KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.

ABSTRACT:

Introduction and design

The introduction of the epidermal growth factor receptor inhibitors (EGFR-I) has increased the treatment options available for patients with metastatic colorectal cancer (mCRC). Two EGFR-I agents currently approved for the treatment of mCRC are the fully human monoclonal antibody panitumumab and the mouse-human chimeric monoclonal antibody cetuximab. While these agents have demonstrated activity across multiple lines of therapy, early studies suggested that clinical benefit was confined to a subset of patients treated. Mutation of the KRAS oncogene has emerged as a powerful negative predictive biomarker to identify patients with mCRC who do not benefit from EGFR-I therapy. Multiple retrospective analyses have demonstrated that clinical benefit from treatment

SUBMITTER: Siddiqui AD 

PROVIDER: S-EPMC2840670 | biostudies-literature | 2010 Apr

REPOSITORIES: biostudies-literature